| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4273068 | The Journal of Sexual Medicine | 2009 | 13 Pages |
Abstract
Recent studies have suggested new ways to optimize utilization of PDE5I not only for the management of ED but also for other sexual concerns in both men and women. Rare but serious toxicities have been reported with PDE5I and, therefore, judicious counseling is indicated before prescribing these medications. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: Updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009;6:2352-2364.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Alan W. MD,